Floatz logo

CRENIGACESTAT

T-cell Lymphoblastic Lymphoma

Eli Lilly and CompanySmall moleculePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

49 Active assets in the T-cell Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Children's Oncology Group
Phase 3BB
Cyclophosphamide
Children's Oncology Group
Phase 3BB
Cytosin-Arabinosid
Princess Maxima Center for Pediatric Oncology
Phase 3BB
ETOPOSIDE
Children's Cancer Group, China
Phase 3BB
Daunorubicin
Children's Oncology Group
Phase 3B

View all 50 →

Same molecule, other indications

CRENIGACESTAT is also rated in:

T-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
41 / 100
View asset →
soft tissue sarcomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →